{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:02:23Z","timestamp":1792036943695,"version":"4.4.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.clml.2021.06.012","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:56:30Z","timestamp":1624521390000},"page":"e865-e875","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Primary Mediastinal B-Cell Lymphoma: A 2021 Update on Genetics, Diagnosis, and Novel Therapeutics"],"prefix":"10.1016","volume":"21","author":[{"given":"Zahoor","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safa Saadat","family":"Afridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeryab","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zarlakhta","family":"Zamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wajeeha","family":"Aiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Ayaz","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrukh T.","family":"Awan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raheel","family":"Iftikhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.06.012_bib0001","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.012_bib0002","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2003-06-1841","article-title":"The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma","volume":"102","author":"Savage","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.012_bib0003","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/modpathol.2011.116","article-title":"Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations","volume":"24","author":"Eberle","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clml.2021.06.012_bib0004","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project","volume":"16","author":"Armitage","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.06.012_bib0005","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1182\/asheducation-2008.1.349","article-title":"Primary mediastinal B-cell lymphoma","author":"Johnson","year":"2008","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2021.06.012_bib0006","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/blood-2012-04-422709","article-title":"Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB\/LMB96 mature B-NHL therapy","volume":"121","author":"Gerrard","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.012_bib0007","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/annonc\/mdj030","article-title":"Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience","volume":"17","author":"Savage","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2021.06.012_bib0008","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.critrevonc.2017.01.009","article-title":"Primary mediastinal large B-cell lymphoma","volume":"113","author":"Martelli","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2021.06.012_bib0009","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.beha.2018.07.001","article-title":"The unique biology and treatment of primary mediastinal B-cell lymphoma","volume":"31","author":"Broccoli","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.clml.2021.06.012_bib0010","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1182\/blood-2011-05-326538","article-title":"The molecular pathogenesis of primary mediastinal large B-cell lymphoma","volume":"118","author":"Steidl","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.012_bib0011","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s12885-017-3269-6","article-title":"The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients","volume":"17","author":"Broccoli","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2021.06.012_bib0012","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11899-014-0219-0","article-title":"Primary mediastinal large B-cell lymphoma","volume":"9","author":"Dabrowska-Iwanicka","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2021.06.012_bib0013","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ctrv.2015.04.006","article-title":"Primary mediastinal large B-cell lymphoma","volume":"41","author":"Bhatt","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clml.2021.06.012_bib0014","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1182\/blood-2011-05-326538","article-title":"The molecular pathogenesis of primary mediastinal large B-cell lymphoma","volume":"118","author":"Steidl","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.012_bib0015","unstructured":"Arnold S Freedman MCA, MD, PhD Jonathan W Friedberg, MD. Up to date. 2020."},{"key":"10.1016\/j.clml.2021.06.012_bib0016","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/ng.2900","article-title":"Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma","volume":"46","author":"Gunawardana","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2021.06.012_bib0017","first-page":"177","article-title":"Roles of the NF-\u03baB pathway in B-lymphocyte biology","volume":"393","author":"Sasaki","year":"2016","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.clml.2021.06.012_bib0018","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1182\/blood-2005-04-1399","article-title":"Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction","volume":"106","author":"Bea","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.012_bib0019","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.clml.2021.06.012_bib0020","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/1097-0142(19881101)62:9<1893::AID-CNCR2820620904>3.0.CO;2-X","article-title":"Mediastinal large cell lymphoma. An uncommon subset of adult lymphoma curable with combined modality therapy","volume":"62","author":"Jacobson","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.06.012_bib0021","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bjh.15778","article-title":"Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions","volume":"185","author":"Lees","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.06.012_bib0022","article-title":"Primary mediastinal B-cell lymphoma: novel precision therapies and future directions","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2021.06.012_bib0023","doi-asserted-by":"crossref","first-page":"228","DOI":"10.4103\/0970-2113.135760","article-title":"Primary mediastinal large B-cell lymphoma: clinical features, prognostic factors and survival with RCHOP in Arab patients in the PET scan era","volume":"31","author":"Al Shemmari","year":"2014","journal-title":"Lung India"},{"key":"10.1016\/j.clml.2021.06.012_bib0024","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1200\/JCO.1999.17.8.2479","article-title":"CNS involvement in primary mediastinal large B-cell lymphoma","volume":"17","author":"Bishop","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.06.012_bib0025","series-title":"Uptodate","first-page":"21","article-title":"Primary mediastinal large B cell lymphoma","author":"Freedman","year":"2020"},{"key":"10.1016\/j.clml.2021.06.012_bib0026","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2141.2005.05661.x","article-title":"Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999","volume":"130","author":"Hamlin","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.06.012_bib0027","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/10245332.2016.1258846","article-title":"A retrospective analysis of outcomes for primary mediastinal large B-cell lymphoma treated with RCHOP followed by radiotherapy or front-line autologous stem cell transplantation","volume":"22","author":"Liu","year":"2017","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2021.06.012_bib0028","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41408-020-0312-7","article-title":"Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up","volume":"10","author":"Zhou","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2021.06.012_bib0029","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.3324\/haematol.2014.111203","article-title":"Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan","volume":"99","author":"Aoki","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.06.012_bib0030","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1002\/cam4.2347","article-title":"Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma","volume":"8","author":"Chan","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2021.06.012_bib0031","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3109\/10428194.2010.550073","article-title":"Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factors in 41 consecutive Asian patients","volume":"52","author":"Tai","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.06.012_bib0032","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3109\/10428194.2012.746684","article-title":"Prognostic significance of rituximab and radiotherapy for patients with primary mediastinal large B-cell lymphoma receiving doxorubicin-containing chemotherapy","volume":"54","author":"Xu","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.06.012_bib0033","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1080\/10428194.2018.1519812","article-title":"R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma","volume":"60","author":"Messmer","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.06.012_bib0034","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjh.15731","article-title":"The management of primary mediastinal B-cell lymphoma: a British Society for Haematology Good Practice Paper","volume":"185","author":"Cwynarski","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.06.012_bib0035","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bjh.14951","article-title":"Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R","volume":"179","author":"Giulino-Roth","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.06.012_bib0036","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijrobp.2015.02.006","article-title":"Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography","volume":"92","author":"Pinnix","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2021.06.012_bib0037","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2013.51.7524","article-title":"[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study","volume":"32","author":"Martelli","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.06.012_bib0038","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","volume":"368","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.06.012_bib0039","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1182\/blood.2019004296","article-title":"Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach","volume":"136","author":"Hayden","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.012_bib0040","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3324\/haematol.2018.192492","article-title":"End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making","volume":"103","author":"Melani","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.06.012_bib0041","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.1999.17.3.784","article-title":"Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 43 patients from the Nebraska Lymphoma Study Group","volume":"17","author":"Abou-Elella","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.06.012_bib0042","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1200\/JCO.1993.11.7.1336","article-title":"Large-cell and immunoblastic lymphoma of the mediastinum: prognostic features and treatment outcome in 57 patients","volume":"11","author":"Kirn","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.06.012_bib0043","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/annonc\/mdq418","article-title":"Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study","volume":"22","author":"Rieger","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2021.06.012_bib0044","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/oxfordjournals.annonc.a057853","article-title":"Stage II large B-cell lymphoma with sclerosis treated with MACOP-B","volume":"2","author":"Bertini","year":"1991","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2021.06.012_bib0045","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3109\/10428199209067612","article-title":"Primary mediastinal B-cell lymphoma with sclerosis: clinical and therapeutic evaluation of 22 patients","volume":"21","author":"Zinzani","year":"1996","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.clml.2021.06.012_bib0046","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2011.38.8835","article-title":"Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study","volume":"30","author":"Swerdlow","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.06.012_bib0047","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma","volume":"34","author":"van Nimwegen","year":"2016","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2021.06.012_bib0048","first-page":"4124","volume":"130","author":"Burke","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.012_bib0049","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1056\/NEJMc1305983","article-title":"Therapy in primary mediastinal B-cell lymphoma","volume":"369","author":"Woessmann","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.06.012_bib0050","series-title":"Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB\/Alliance 50303","author":"Wilson","year":"2016"},{"issue":"6","key":"10.1016\/j.clml.2021.06.012_bib0051","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.3324\/haematol.2019.238675","article-title":"Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas","volume":"106","author":"Svoboda","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.06.012_bib0052","first-page":"187","article-title":"Primary mediastinal large B-cell lymphoma with sclerosis: a clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy","volume":"86","author":"Zinzani","year":"2001","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.06.012_bib0053","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1634\/theoncologist.2011-0275","article-title":"Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care","volume":"17","author":"Vassilakopoulos","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2021.06.012_bib0054","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/bjh.14287","article-title":"Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial","volume":"175","author":"Gleeson","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.clml.2021.06.012_bib0055","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/bjh.15051","article-title":"R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis","volume":"180","author":"Shah","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.06.012_bib0056","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ejh.13337","article-title":"Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma","volume":"104","author":"Malenda","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2021.06.012_bib0057","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.06.012_bib0058","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.clml.2021.06.012_bib0059","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1200\/JCO.2009.26.5942","article-title":"Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-cell lymphoma","volume":"28","author":"Moskowitz","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.06.012_bib0060","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1182\/blood-2018-05-850305","article-title":"FDG-PET in PMBCL: which heterogeneity?","volume":"132","author":"Meignan","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.012_bib0061","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.ijrobp.2016.02.057","article-title":"Prognostic role of pre-radiation therapy 18f-fluorodeoxyglucose positron emission tomography for primary mediastinal B-Cell lymphomas treated with R-CHOP or R-CHOP-like chemotherapy plus radiation","volume":"95","author":"Filippi","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2021.06.012_bib0062","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1182\/blood-2014-12-616474","article-title":"Utility of baseline 18FDG-PET\/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma","volume":"126","author":"Ceriani","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.012_bib0063","doi-asserted-by":"crossref","first-page":"8041","DOI":"10.1200\/JCO.2020.38.15_suppl.8041","article-title":"Role of Radiotherapy and Dose-Densification of R-CHOP in Primary Mediastinal B-Cell Lymphoma: A Subgroup Analysis of the Unfolder Trial of the German Lymphoma Alliance (GLA)","volume":"38","author":"Held","year":"2020","journal-title":"J Clinic Oncol"},{"key":"10.1016\/j.clml.2021.06.012_bib0064","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/ajh.24325","article-title":"Improved survival with combined modality therapy in the modern era for primary mediastinal B-cell lymphoma","volume":"91","author":"Jackson","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.clml.2021.06.012_bib0065","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/pro6.1070","article-title":"Radiotherapy after immunochemotherapy improves outcomes in patients with primary mediastinal large B-cell lymphoma","volume":"3","author":"Avil\u00e9s","year":"2019","journal-title":"Precis Radiat Oncol"},{"key":"10.1016\/j.clml.2021.06.012_bib0066","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.101","article-title":"High-dose chemotherapy followed by autologous stem cell transplantation for relapsed\/refractory primary mediastinal large B-cell lymphoma","volume":"5","author":"Aoki","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2021.06.012_bib0067","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/10428190802108870","article-title":"Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma","volume":"49","author":"Kuruvilla","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.clml.2021.06.012_bib0068","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/blood.V91.2.717","article-title":"Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation","volume":"91","author":"Sehn","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.012_bib0069","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.bbmt.2018.06.009","article-title":"Outcomes of relapsed and refractory primary mediastinal (thymic) large B cell lymphoma treated with second-line therapy and intent to transplant","volume":"24","author":"Vardhana","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.06.012_bib0070","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/BF00873962","article-title":"A phase II trial of oral etoposide with mitoxantrone and ifosfamide\/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and\/or refractory lymphomas","volume":"12","author":"Romaguera","year":"1994","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clml.2021.06.012_bib0071","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4103\/2277-9175.201687","article-title":"Comparison of ifosfamide, carboplatin and etoposide versus etoposide, steroid, and cytarabine cisplatin as salvage chemotherapy in patients with refractory or relapsed Hodgkin's lymphoma","volume":"6","author":"Mehrzad","year":"2017","journal-title":"Adv Biomed Res"},{"issue":"34","key":"10.1016\/j.clml.2021.06.012_bib0072","first-page":"3291","article-title":"The role of pembrolizumab in relapsed\/refractory primary mediastinal large B-cell lymphoma","volume":"37","author":"Tomassetti","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2021.06.012_bib0073","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2016-12-758383","article-title":"Safety and tolerability of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma","volume":"130","author":"Zinzani","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.012_bib0074","unstructured":"Sharp M, Corp. D. A study of pembrolizumab (MK-3475) in participants with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) (MK-3475-A33\/KEYNOTE-A33). 2020 May 11. Available at: https:\/\/ClinicalTrials.gov\/show\/NCT04317066; 2020."},{"key":"10.1016\/j.clml.2021.06.012_bib0075","unstructured":"ONLUS F.I.L. A Study of SGN-35 (brentuximab vedotin) of patients with relapsed or refractory PMLBCL. 2013 May 23. Available at: https:\/\/ClinicalTrials.gov\/show\/NCT02423291; 2013."},{"key":"10.1016\/j.clml.2021.06.012_bib0076","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1182\/blood-2017-01-764258","article-title":"Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial","volume":"129","author":"Zinzani","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.012_bib0077","unstructured":"Pennsylvania ACCotUo. Brentuximab vedotin and chemotherapy in CD30+ PMBL, diffuse large B-cell, and grey zone lymphoma patients. 2013 October 15. Available at: https:\/\/ClinicalTrials.gov\/show\/NCT01994850; 2013."},{"key":"10.1016\/j.clml.2021.06.012_bib0078","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1200\/JCO.19.01492","article-title":"Nivolumab combined with brentuximab vedotin for relapsed\/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 study","volume":"37","author":"Zinzani","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.06.012_bib0079","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.06.012_bib0080","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.06.012_bib0081","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.06.012_bib0082","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/intimm\/dxu089","article-title":"Unleashing the clinical power of T cells: CD19\/CD3 bi-specific T cell engager (BiTE\u00ae) antibody construct blinatumomab as a potential therapy","volume":"27","author":"Zimmerman","year":"2015","journal-title":"Int Immunol"},{"key":"10.1016\/j.clml.2021.06.012_bib0083","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.06.012_bib0084","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.012_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-021-00430-6","article-title":"Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment","volume":"11","author":"van der Horst","year":"2021","journal-title":"Blood Cancer J"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021002421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021002421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:37:16Z","timestamp":1761871036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021002421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":85,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S2152265021002421"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.06.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary Mediastinal B-Cell Lymphoma: A 2021 Update on Genetics, Diagnosis, and Novel Therapeutics","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}